{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"125"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"groups":[{"description":"Patients receive Akt/ERK inhibitor ONC201 125 mg PO every 7 days. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"ONC201 125 mg"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"21 days","title":"Recommended Phase 2 Dose (RP2D) (Phase I)","type":"PRIMARY","unitOfMeasure":"mg"}